1626

## DEC 2 7 2004

## TRANSMITTAL LETTER (General - Patent Pending)

Docket No. PC22037B/US

In Re Application of:

Allerton et al.

| Application No. | Filing Date    | Examiner    | Customer No. | Group Art Unit | Confirmation No. |
|-----------------|----------------|-------------|--------------|----------------|------------------|
| 10/812,143      | March 29, 2004 | L. Stockton | 26648        | 1626           | 3239             |

Title: 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS

## **COMMISSIONER FOR PATENTS:**

Transmitted herewith is:

Amendment Transmittal; Amendment and Reply to Office Action; Application Data Sheet; Itemized Postcard.

in the above identified application.

☐ A check in the amount of

is attached.

as described below.

The Director is hereby authorized to charge and credit Deposit Account No. 19-1025

Charge the amount of

Credit any overpayment.

Charge any additional fee required.

□ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Signature

Date

Dated: December 21, 2004

Daniel S. Kasten, Reg. No. 45,363 Pharmacia Corporation of Pfizer Inc.

P.O. Box 1027

Chesterfield, Missouri 63006

314.274.5218

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

December 21, 2004

Signature of Person Mailing Correspondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence

CC:

|  | MENT TRANSMIT                    | Docket No. PC22037B/US   |                   |      |                        |  |  |  |  |  |
|--|----------------------------------|--------------------------|-------------------|------|------------------------|--|--|--|--|--|
| Application No. 10/812,143   | Filing Date<br>March 29, 2004    | Examiner Laura Stockton  | Customer<br>26648 | No.  | Group Art Unit<br>1626 | Confirmation No.                                 |  |  |  |  |
| Invention: 2 (INVIDAZOLYL)2-ALKOXYPROPANOIC ACIDS  |                                  |                          |                   |      |                        |  |  |  |  |  |
| COMMISSIONER FOR PATENTS:  Transmitted herewith is an amendment in the above-identified application.   |                                  |                          |                   |      |                        |  |  |  |  |  |
| The fee has been calculated and is transmitted as shown below.   |                                  |                          |                   |      |                        |  |  |  |  |  |
|  |                                  | CLAIMS AS AM             | ENDED             |      |                        |  |  |  |  |  |
|  | CLAIMS REMAINING AFTER AMENDMENT | HIGHEST # PREV. PAID FOR | NUMBER EXTRA      |      | RATE                   | ADDITIONAL<br>FEE                                |  |  |  |  |
| TOTAL CLAIMS   | 1 -                              | 178 =                    |                   | 0 x  | \$50.00                | \$0.00   |  |  |  |  |
| INDEP. CLAIMS  | 1 -                              | 2 =                      |                   | 0 x  | \$200.00               | \$0.00   |  |  |  |  |
| Multiple Dependen  | t Claims (check if app           | licable)                 |                   |      |                        | \$0.00   |  |  |  |  |
|  |                                  | TOTAL ADDITIONAL F       | FEE FOR THIS AN   | /ENI | DMENT                  | \$0.00   |  |  |  |  |
| <ul> <li>No additional fee is required for amendment.</li> <li>□ Please charge Deposit Account No. in the amount of</li> <li>□ A check in the amount of to cover the filing fee is enclosed.</li> <li>☑ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1025</li> <li>☑ Any additional filing fees required under 37 C.F.R. 1.16.</li> <li>☑ Any patent application processing fees under 37 CFR 1.17.</li> <li>□ Payment by credit card. Form PTO-2038.</li> <li>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</li> </ul> |                                  |                          |                   |      |                        |  |  |  |  |  |
| Daniel S. Kasten, I  | <del>-</del> .                   |                          | Dated: Decemb     |      |                        |  |  |  |  |  |
| Pharmacia Corporation of Pfizer, Inc.  P.O. Box 1027  Chesterfield, Missouri 63006  314.274.5218  I hereby certify that this correspondence is being deported the United States Postal Service with sufficient postage class mail in an envelope addressed to "Commissioner for P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.86]  |                                  |                          |                   |      |                        | ficient postage as first mmissioner for Patents, |  |  |  |  |

314.274.5218

December 21, 2004

(Date)

ignature of Person Mailing Correstondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence

PC22037B-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Allerton et al.

**PATEN** 

**GROUP ART UNIT: 1626** 

SERIAL NUMBER: 10/812,143

**EXAMINER: Stockton, Laura Lynne** 

FILED: 03/29/04

TITLE: 3-(ImidazolyI)-2-Alkoxypropanoic Acids

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450 on December 21, 2004

Linda Cooper

AMENDMENT & REPLY TO OFFICE ACTION

Commissioner of Patents Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated September 28, 2004, please amend the above-identified application as indicated and enter the following remarks.